Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222336 | 0.86 | ALDH1A1 (0.61) | TSHRGAAKDM4EHPGDALDH1A1 | |
| SCHEMBL12491925 | 0.85 | GAA (0.70) | TSHRGAAKDM4EHPGDALDH1A1 | |
| SCHEMBL7394648 | 0.84 | KDM4E (0.66) | TSHRGAAKDM4EHPGDALDH1A1 | |
| SCHEMBL5855304 | 0.83 | KDM4E (0.64) | TSHRGAAKDM4EHPGDALDH1A1 | |
| SCHEMBL3814103 | 0.81 | GAA (0.69) | TSHRGAAKDM4EHPGDALDH1A1 | |
| SCHEMBL1222245 | 0.81 | KDM4E (0.66) | TSHRGAAKDM4EHPGDALDH1A1 | |
| SCHEMBL7503385 | 0.80 | KDM4E (0.70) | TSHRGAAKDM4EHPGDALDH1A1 | |
| SCHEMBL21479628 | 0.80 | KDM4E (0.60) | TSHRGAAKDM4EHPGDALDH1A1 | |
| SCHEMBL15247363 | 0.80 | KDM4E (0.60) | TSHRGAAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2330242 | 0.80 | GAA (0.82) | TSHRGAAKDM4EHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144906-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-12-05 | — | — | US | disclosed |
| US-7030143-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-7022723-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1634876-A2 | Heterocyclic compounds for the treatment of hyperlipidemia agents | Nippon Shinyaku Co., Ltd. (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-6998412-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-02-14 | — | — | US | disclosed |
| CN-1238347-C | Heterocyclic derivatives | NIPPON SHINYAKU CO LTD (JP) | 2006-01-25 | — | — | CN | disclosed |
| US-20050009892-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20050009785-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040162325-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2004-08-19 | — | — | US | disclosed |
| US-20030166697-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| CN-1430612-A | Hete rocyclic derivatives | NIPPON SHINYAKU CO LTD (JP) | 2003-07-16 | — | — | CN | disclosed |
| EP-1295875-A1 | HETEROCYCLIC COMPOUNDS | Nippon Shinyaku Co., Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
| EP-0421365-B1 | Tetrazoleacetic acid derivatives having aldose reductase inhibitory activity | WAKAMOTO PHARMA CO LTD (JP) | 1997-03-05 | — | — | EP | disclosed |
| US-RE35321-E | ANTIDIABETIC AGENT | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1996-08-27 | — | — | US | disclosed |
| US-5068239-A | Antidiabetic agent | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1991-11-26 | — | — | US | disclosed |
| EP-0421365-A2 | Tetrazoleacetic acid derivatives having aldose reductase inhibitory activity | Wakamoto Pharmaceutical Co., Ltd. (JP) | 1991-04-10 | — | — | EP | disclosed |
| US-4419363-A | ADRENERGIC BLOCKING AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-12-06 | — | — | US | disclosed |
| US-4346111-A | CARDIOVASCULAR DISORDERS, HYPOTENSIVE AGENTS, ADRENERGIC BLOCKING AGENTS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1982-08-24 | — | — | US | disclosed |
| US-4318921-A | HYPOTENSIVE AGENTS; ADRENERGIC BLOCKING AGENTS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1982-03-09 | — | — | US | disclosed |
| US-4211878-A | ADRENERGIC BLOCKING AGENTS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009785-A1 | Heterocyclic compounds | LIPC, GPR119, APOB | TSHR 1666/4885GAA 565/4885KDM4E 1600/4885 |
| US-20050009892-A1 | Heterocyclic compounds | GPR119, LIPC, LIPE | TSHR 2487/4885GAA 804/4885KDM4E 1141/4885 |
| US-20040162325-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | TSHR 2672/4885GAA 780/4885KDM4E 1321/4885 |
| US-20030166697-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | TSHR 2672/4885GAA 780/4885KDM4E 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.